Social Patterning and Stability of Intention to Accept a COVID-19 Vaccine in Scotland: Will Those Most at Risk Accept a Vaccine?
Abstract
:1. Introduction
2. Materials and Methods
2.1. Participants and Procedure
2.2. Questionnaire
2.2.1. Demographics and Health
2.2.2. COVID-19 Vaccination Intention
2.3. Statistical Analysis
3. Results
3.1. RQ1: What Proportion of People Would Accept a Vaccine for COVID-19?
3.2. RQ2—Is COVID-19 Vaccine Acceptance Stable over Time in the Context of Different Infection Levels and Restrictions?
3.3. RQ3: What Sociodemographic and Health Factors Are Associated with Intention to Accept a Future Vaccine for COVID-19?
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- De Figueiredo, A.; Simas, C.; Karafillakis, E.; Paterson, P.; Larson, H.J. Mapping global trends in vaccine confidence and investigating barriers to vaccine uptake: A large-scale retrospective temporal modelling study. Lancet 2020, 396, 898–908. [Google Scholar] [CrossRef]
- Larson, H.J.; De Figueiredo, A.; Xiahong, Z.; Schulz, W.S.; Verger, P.; Johnston, I.G.; Jones, N.S. The state of vaccine confidence 2016: Global insights through a 67-country survey. EBioMedicine 2016, 12, 295–301. [Google Scholar] [CrossRef] [Green Version]
- Wellcome Trust. Wellcome Global Monitor. 2018. Available online: https://wellcome.ac.uk/reports/wellcome-global-monitor/2018 (accessed on 20 November 2020).
- Jorgensen, P.; Mereckiene, J.; Cotter, S.; Johansen, K.; Tsolova, S.; Brown, C. How close are countries of the WHO European Region to achieving the goal of vaccinating 75% of key risk groups against influenza? Results from national surveys on seasonal influenza vaccination programmes, 2008/2009 to 2014/2015. Vaccine 2018, 36, 442–452. [Google Scholar] [CrossRef]
- MacDonald, N.E. The SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [Google Scholar] [CrossRef]
- Lane, S.; MacDonald, N.E.; Marti, M.; Dumolard, L. Vaccine hesitancy around the globe: Analysis of three years of WHO/UNICEF Joint Reporting Form data-2015–2017. Vaccine 2008, 36, 3861–3867. [Google Scholar] [CrossRef] [PubMed]
- Larson, H.J.; Jarrett, C.; Eckersberger, E.; Smith, D.M.D.; Paterson, P. Understanding vaccine hesitancy around vaccines and vaccination from a global perspective: A systematic review of published literature, 2007–2012. Vaccine 2014, 32, 2150–2159. [Google Scholar] [CrossRef] [PubMed]
- Brewer, N.T.; Chapman, G.B.; Rothman, A.J.; Leask, J.; Kempe, A. Increasing vaccination: Putting psychological science into action. Psychol. Sci. Public Interest 2017, 18, 149–207. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schmid, P.; Rauber, D.; Betsch, C.; Lidolt, G.; Denker, M.L. Barriers of influenza vaccination intention and behavior–a systematic review of influenza vaccine hesitancy, 2005–2016. PLoS ONE 2017, 12, e0170550. [Google Scholar] [CrossRef] [PubMed]
- Bish, A.; Yardley, L.; Nicoll, A.; Michie, S. Factors associated with uptake of vaccination against pandemic influenza: A systematic review. Vaccine 2011, 29, 6472–6484. [Google Scholar] [CrossRef] [PubMed]
- Brien, S.; Kwong, J.C. The determinants of 2009 pandemic A/H1N1 influenza vaccination: A systematic review. Vaccine 2012, 30, 1255–1264. [Google Scholar] [CrossRef]
- Fabry, P.; Gagneur, A.; Pasquier, J.-C. Determinants of A(H1N1) vaccination: Cross sectional study in a population of pregnant women in Quebec. Vaccine 2011, 29, 1824–1829. [Google Scholar] [CrossRef] [PubMed]
- Han, K.Y.J.; Michie, S.; Potts, H.W.; Rubin, G.J. Predictors of influenza vaccine uptake during the 2009/10 influenza A H1N1v (‘swine flu’) pandemic: Results from five national surveys in the United Kingdom. Prev. Med. 2016, 84, 57–61. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seale, H.; Heywood, A.E.; McLaws, M.L.; Ward, K.F.; Lowbridge, C.P.; Van, D.; MacIntyre, C.R. Why do I need it? I am not at risk! Public perceptions towards the pandemic (H1N1) 2009 vaccine. BMC Infect. Dis. 2010, 99. [Google Scholar] [CrossRef] [Green Version]
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2020. [Google Scholar] [CrossRef] [PubMed]
- Rhodes, A.; Hoq, M.; Measey, M.-A.; Danchin, M. Intention to vaccinate against COVID-19 in Australia. Lancet Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Malik, A.M.; McFadden, S.M.; Elharake, J.; Omer, S.B. Determinants of COVID-19 vaccine acceptance in the US. EClinical Med. 2020. [Google Scholar] [CrossRef]
- IPSOS MORI: News Three in Four Adults Globally Say They Would Get a Vaccine for COVID-19. Available online: https://www.ipsos.com/ipsos-mori/en-uk/three-four-adults-globally-say-they-would-get-vaccine-covid-19 (accessed on 10 November 2020).
- The COCONEL Group. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect. Dis. 2020, 20, 769–770. [Google Scholar] [CrossRef]
- Dodd, R.H.; Cvejic, E.; Bonner, C.; Pickles, K.; McCaffery, K.J. Sydney Health Literacy Lab COVID-19 group. Willingness to vaccinate against COVID-19 in Australia. Lancet Infect. Dis. 2020. [Google Scholar] [CrossRef]
- Bartsch, S.M.; O’Shea, K.J.; Ferguson, M.C.; Bottazzi, M.E.; Wedlock, P.T.; Strych, U.; McKinnell, J.A.; Siegmund, S.S.; Cox, S.N.; Hotez, P.J.; et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. Am. J. Prev. Med. 2020, 59, 493–503. [Google Scholar] [CrossRef]
- Office for National Statistics Deaths involving COVID-19 by Local Area and Socioeconomic Deprivation: Deaths Occurring between 1 March and 31 July 2020. Available online: https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/bulletins/deathsinvolvingcovid19bylocalareasanddeprivation/deathsoccurringbetween1marchand31july2020 (accessed on 12 November 2020).
- Dube, E.; Leask, J.; Wolff, B.; Hickler, B.; Balaban, V.; Hosein, E.; Habersaat, K. The WHO Tailoring Immunization Programmes (TIP) approach: Review of implementation to date. Vaccine 2018, 36, 1509–1515. [Google Scholar] [CrossRef]
- Thomson, A.; Vallée-Tourangeau, G.; Suggs, L.S. Strategies to increase vaccine acceptance and uptake: From behavioral insights to context-specific, culturally-appropriate, evidence-based communications and interventions. Vaccine 2018, 36, 6457–6458. [Google Scholar] [CrossRef] [PubMed]
- Dube, E.; Gagnon, D.; MacDonald, N.E. The SAGE Working Group on Vaccine Hesitancy. Strategies intended to address vaccine hesitancy: Review of published reviews. Vaccine 2015, 33, 4191–4203. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Michie, S.; Atkins, L.; West, R. The Behaviour Change Wheel: A Guide to Designing Interventions; Silverback: London, UK, 2014. [Google Scholar]
- Michie, S.; Stralen, M.M.; West, R. The behaviour change wheel: A new method for characterising and designing behaviour change interventions. Implement. Sci. 2011, 6, 42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cane, J.; O’Connor, D.; Michie, S. Validation of the theoretical domains framework for use in behaviour change and implementation research. Implement. Sci. 2012, 7, 37. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Michie, S.; Richardson, M.; Johnston, M.; Abraham, C.; Francis, J.; Hardeman, W.; Wood, C.E. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: Building an international consensus for the reporting of behavior change interventions. Ann. Behav. Med. 2013, 46, 81–95. [Google Scholar] [CrossRef] [PubMed]
- Williams, L.; Gallant, A.J.; Rasmussen, S.; Brown Nicholls, L.A.; Cogan, N.; Deakin, K.; Young, D.; Flowers, P. Towards intervention development to increase the uptake of COVID-19 vaccination among those at high risk: Outlining evidence-based and theoretically informed future intervention content. Br. J. Health Psychol. 2020, 25, 1039–1054. [Google Scholar] [CrossRef] [PubMed]
Time 1 | Time 2 | |||
---|---|---|---|---|
Variables | n | % | n | % |
Age | ||||
18–49 | 1847 | 53.8 | 974 | 48.3 |
50+ | 1578 | 45.9 | 1034 | 51.5 |
Gender | ||||
Female | 2719 | 79.1 | 1632 | 82.1 |
Male | 666 | 19.4 | 355 | 17.9 |
Ethnicity | ||||
White | 3308 | 96.3 | 1949 | 96.7 |
BAME | 101 | 2.9 | 52 | 2.6 |
Household income | ||||
<£16,000 | 334 | 9.7 | 196 | 9.7 |
£16,000–£29,999 | 611 | 17.8 | 348 | 17.3 |
£30,000–£59,000 | 1203 | 35.0 | 717 | 35.6 |
£60,000+ | 902 | 26.3 | 519 | 25.7 |
Education level | ||||
No quals/left school 16 | 168 | 4.9 | 77 | 3.8 |
High school/college | 780 | 22.7 | 439 | 21.8 |
University | 2435 | 70.9 | 1467 | 72.8 |
High risk/shielding | ||||
Yes | 508 | 14.8 | 316 | 15.7 |
No | 2855 | 83.1 | 1677 | 83.2 |
COVID-19 Vaccine Intention | Time 1 (National Lockdown) | Time 2 (Easing of Restrictions) | ||
---|---|---|---|---|
N | % | N | % | |
I definitely would not want to receive it | 54 | 3% | 65 | 4% |
I probably would not want to receive it | 79 | 4% | 84 | 5% |
Unsure | 301 | 17% | 262 | 14% |
I probably would want to receive it | 498 | 27% | 506 | 27% |
I definitely would want to receive it | 904 | 49% | 919 | 50% |
Vaccine hesitant | 850 | 26% | 416 | 22.5% |
Vaccine willing | 2406 | 74% | 1433 | 77.5% |
Variable | p-Value | Comparison | Coefficient | p-Value |
---|---|---|---|---|
Age | <0.001 | 50+ vs. 18–49 | 0.70 | - |
Gender | 0.190 | Male vs. Female | 1.11 | - |
Ethnicity | 0.018 | White vs. BAME | 1.72 | - |
Education | <0.001 | High school/College vs. No qualifications/left at 16 | 1.98 | <0.001 |
University vs. No qualifications/left at 16 | 2.78 | <0.001 | ||
Household income | <0.001 | £16,000–£29,999 vs. <£16,000 | 1.11 | 0.441 |
£30,000–£59,999 vs. <£16,000 | 1.39 | 0.009 | ||
£60,000+ vs. <£16,000 | 1.97 | <0.001 | ||
High risk/shielding | 0.012 | Yes vs. No | 1.31 | - |
Variable | p-Value | Comparison | Coefficient | 95% CI | p-Value |
---|---|---|---|---|---|
Ethnicity | <0.001 | White vs. BAME | 2.91 | 1.75–4.81 | - |
Education | <0.001 | High school/College vs. no qualifications/left at 16 | 1.90 | 1.56–2.32 | <0.001 |
University vs. no qualifications/left at 16 | 2.50 | 1.95–3.21 | <0.001 | ||
Household income | <0.001 | £16,000–£29,999 vs. <£16,000 | 1.05 | 0.80–1.38 | 0.743 |
£30,000–£59,999 vs. <£16,000 | 1.27 | 0.98–1.65 | 0.077 | ||
£60,000+ vs. <£16,000 | 1.82 | 1.35–2.45 | <0.001 | ||
High risk/shielding | <0.001 | Yes vs. no | 1.95 | 1.53–2.49 | - |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Williams, L.; Flowers, P.; McLeod, J.; Young, D.; Rollins, L.; The CATALYST Project Team. Social Patterning and Stability of Intention to Accept a COVID-19 Vaccine in Scotland: Will Those Most at Risk Accept a Vaccine? Vaccines 2021, 9, 17. https://doi.org/10.3390/vaccines9010017
Williams L, Flowers P, McLeod J, Young D, Rollins L, The CATALYST Project Team. Social Patterning and Stability of Intention to Accept a COVID-19 Vaccine in Scotland: Will Those Most at Risk Accept a Vaccine? Vaccines. 2021; 9(1):17. https://doi.org/10.3390/vaccines9010017
Chicago/Turabian StyleWilliams, Lynn, Paul Flowers, Julie McLeod, David Young, Lesley Rollins, and The CATALYST Project Team. 2021. "Social Patterning and Stability of Intention to Accept a COVID-19 Vaccine in Scotland: Will Those Most at Risk Accept a Vaccine?" Vaccines 9, no. 1: 17. https://doi.org/10.3390/vaccines9010017
APA StyleWilliams, L., Flowers, P., McLeod, J., Young, D., Rollins, L., & The CATALYST Project Team. (2021). Social Patterning and Stability of Intention to Accept a COVID-19 Vaccine in Scotland: Will Those Most at Risk Accept a Vaccine? Vaccines, 9(1), 17. https://doi.org/10.3390/vaccines9010017